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be enhanced with an introduction of such QA tool in the 
clinic. 
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Purpose/Objective: Energy of gamma ray radiotherapy is 
transferred by electrons in both target tumors and 
surrounding normal tissues. If electrons, generated in body 
tissues, could be specifically removed in critical normal 
tissues, these normal tissues will be spared without 
compromising the target tumor dose. The purpose of this 
study was to present a new method of in-body electron 
modulation, using a magnetic field, to reduce dose of normal 
tissues near a target tumor. 
Materials and Methods: Two tissue equivalent phantoms 
which composed with normal tissue area (NTA) and target 
tumor area (TTA) were developed; 1) single beam model 
(SBM) phantom to analyze a longitudinal percentage depth 
dose curve, and 2) multi-beam model (MBM) phantom to 
analyze a cross sectional dose of both NTA and TTA dose. 
Distance of a gap between NTA and TTA were 5mm. The 
phantoms were irradiated using 3x3cm sized field of 6MeV 
photon beam with or without 0.3T local magnetic field 
through beam path to remove forward electrons. Absorbed 
dose were measured in each NTA and TTA. 
Results: With magnetic field applied, bending effect of the 
electron beam path was visualized in longitudinal film data. 
The percentage depth dose curve of SBM phantom showed 
about 40% dose reduction in NTA and almost no dose 
difference in TTA with magnetic field. Re-build up 
phenomenon were observed in the gap between NTA and 
TTA. In MBM phantom experiment, dose of the NTA were 300 
cGy and 190 cGy, without and with magnetic field, 
respectively (36.7 % dose reduction). And dose of the TTA 
were 600 cGy and 580 cGy, without and with magnetic field, 
respectively (3.3% dose difference). 
Conclusions: Applying local magnetic field could reduce dose 
of normal tissues near a target by removing forward electrons 
without compromising target dose in gamma ray 
radiotherapy. Further in vivo studies are needed to confirm 
biologic significance of this phantom experiment. 
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Purpose/Objective: Head and neck cancer patients often 
undergo important soft tissue changes during radiotherapy. 
To assess the actual delivered dose recalculated on the daily 
IGRT images is often time consuming and mostly not routinely 
feasible. The aim of this study was to assess whether daily 
dose recalculations are necessary and and to develop a 
recommendataion for daily practice. 
Materials and Methods: Six head and neck cancer patients 
treated in our department with helical tomotherapy were 
analyzed for this work in progress. Total fraction number was 
32 to 34 per patient. All patients underwent daily IGRT by 
MVCT at the TomoTherapy Unit. For each patient, we 
retrospectively performed daily dose recalculations on the 
MVCTs to assess the influence of soft tissue changes on dose 
distributions. We evaluated several summation doses: daily 
dose summations (DayDo), dose recalculations/sumations 
every second day (2Do), once a week (1WeDo) and once 
every two weeks (2WeDo). For the days when the dose 
recalculation on the MVCT was not performed, the day(s) 
before were summed up. In order to avoid dose recalculation 
errors due to recalculation on MVCTS, we compared the 
summation doses with the doses recalculated on the first 
MVCT (MVCT1Do) (expected to be very similar to the planning 
CT) times the total number of fractions. 
We analyzed the mean dose (Dmean), the maximum dose 
(Dmax), the Dmax in 1 cm³ (D1cc) and the minimum dose 
(Dmin). For the PTV: Dmax, Dmin and Dmean; for the spinal 
cord (SC): Dmax, D1cc, for the SC+5mm: Dmax, D1cc; for the 
parotid glands (PG): Dmean; for the mandible (Mnd): Dmean, 
Dmax. 
Results: Overall, for all OAR the median changes as 
compared to MVCT1Do was 3.3Gy (range: +8Gy (for SC+5mm) 
to -8.73Gy (Mnd)). The median PTV Dmax change as 
compared to MVCT1Do was -0.71Gy (+0.13Gy to -3.01Gy), the 
Dmin +4.24Gy (+5.39Gy to -1.59Gy) and the Dmean change 
was -0.07 (0.09Gy to -0.26Gy). The differences between the 
scenarios (DayDo as compared to 2Do , 1WeDo and 2WeDo) 
were small and mostly not statistically significant. The only 
statistically significant differences between the scenarios 
were for the PTV Dmean and the SC Dmax and D1cc. The 
overall median differences in Gy (range) between the DayDo 
and the 2Do, 1WeDo and 2WeDo are presented in the table. 
 
Conclusions: Significant changes can be observed during 
treatment. Daily dose recalculations remain a 'gold' standard. 
Nonetheless less time consuming scenarios can be used for 
some structures to assess the actual delivered doses during 
treatment with an implication on adaptive replanning. 
   
 
 
